This is a routine, small-proportional director sale with no material signal. Monitor for any follow-on Form 4 filings to confirm execution, but no trading action is warranted based on this filing alone.
KRYS drugs
KRYS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $335.73entry
- T+1 · 3mo ago −0.87%α −0.19% · $332.82
- T+5 · 3mo ago +1.78%α +2.97% · $341.72
- T+20 · 2mo ago +0.28%α +2.26% · $336.68
- T+60 · 7d ago −8.71%α −5.76% · $306.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Dino A. Rossi filed a Form 144 notice of intent to sell 25,000 shares of Krystal Biotech common stock through Goldman Sachs, with an estimated aggregate market value of approximately $8.3 million based on the filing date. This represents about 0.08% of the company's $9.7B market cap and a modest portion of Rossi's total holdings of ~29.6 million shares. The sale is routine for a director and does not signal insider concern given the small proportional size and the company's strong institutional support (89% analyst bullish).
Key Facts
- Director Dino A. Rossi filed Form 144 to sell 25,000 shares of KRYS common stock.
- Estimated aggregate market value of the proposed sale is approximately $8.3 million.
- Rossi holds approximately 29.6 million shares post-sale, making this a ~0.08% reduction in his position.
- The shares were acquired from the public market on 09/22/2017, indicating long-term holding.
- Sale is to be executed through Goldman Sachs & Co. LLC.
Financial Impact
Proposed sale of 25,000 shares valued at ~$8.3 million, representing ~0.08% of KRYS's $9.7B market cap.
Risk Factors
- Insider may still decide not to execute the sale despite filing the notice.
- No material risk to the company's fundamentals or stock price from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001958244-26-000513 |
| Document: 0001958244-26-000513-index.html | 0001958244-26-000513 |
| Document: 0001958244-26-000513.txt | 0001958244-26-000513 |
Track record
18 reports on KRYS
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +26.60% at T+60 after the May 4, 2026 report. 6 of 7 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $295.90 Now $297.90 +0.68% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Bearish 5/10 Entry $332.29 Now $297.90 +10.35% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $321.42 Now $297.90 −7.32% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $320.13 Now $297.90 −6.94% settles Nov 19
- Oct 15, 20264w ago 8-K Bullish 6/10 Entry $330.00 to $305.68 Now $297.90 −9.73% ▼ −7.37% −5.47% vs SPY
- Sep 4, 202610w ago Insider Cluster Bearish 5/10 Entry $351.26 to $326.81 Now $297.90 +15.19% ▲ +6.96% +8.67% vs SPY
- Aug 14, 202613w ago 144 Neutral 2/10 Viewing Entry $335.73 to $336.68 Now $297.90 −11.27% ▲ +0.28% +2.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers